Company Overview - Akari Therapeutics is a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for cancer treatment [3] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells [3] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] Product Development - PH1 is differentiated from current ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - AKTX-101 has the potential to work synergistically with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Events - Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech on August 19, 2025, at 2:00 PM ET [1]

Core Insights - Akari Therapeutics is focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][4] - The company’s lead candidate, AKTX-101, utilizes a novel spliceosome modulator payload, PH1, which has shown significant preclinical activity [4] Company Overview - Akari Therapeutics is an oncology biotechnology company that has developed PH1, a spliceosome modulator designed to disrupt RNA splicing within cancer cells [4] - PH1 is differentiated from traditional ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, and it has demonstrated the ability to induce cancer cell death while activating immune cells [4] - AKTX-101 targets the Trop2 receptor on cancer cells, delivering the PH1 payload directly into tumors, and has shown prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - The company is conducting ongoing research to further understand the effects of PH1 and its potential to disrupt key drivers of cancer cell growth [3][4] - Akari is generating validating data on PH1 to advance its lead asset and explore other undisclosed targets [4]

Core Insights - Akari Therapeutics is advancing its research on PH1, a novel spliceosome modulator that induces cancer cell death and activates the immune system to combat cancer [1][4] - The company is focused on developing antibody drug conjugates (ADCs) utilizing the PH1 payload, with ongoing preclinical studies expected to yield new data by year-end [1][3] Company Overview - Akari Therapeutics specializes in oncology biotechnology, developing innovative ADCs with a unique mechanism of action through the PH1 payload, which disrupts RNA splicing [4] - The lead candidate, AKTX-101, targets the Trop2 receptor and has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - Ongoing research aims to explore the effects of PH1 on key oncogenic drivers such as KRAS, BRAF, and FGFR3, with preliminary data anticipated soon [2][3] - The PH1 payload has demonstrated the ability to induce cytotoxicity in cancer cells and activate immune responses, potentially leading to improved therapeutic outcomes [2][6]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [1][3] - The company has developed its first novel payload, PH1, which is a spliceosome inhibitor designed to disrupt RNA splicing within cells [3] - PH1 is differentiated from current ADC payloads that utilize Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] Lead Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - The candidate has potential synergistic effects with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Recent Developments - Abizer Gaslightwala, the CEO of Akari, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference, discussing his dedication to the company and its programs [1][2] - The on-demand video webcast of the conference is available on virtualinvestorco.com and the company's website [2]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][4] - The company has developed its first novel payload, PH1, which is a spliceosome inhibitor designed to disrupt RNA splicing within cells, differentiating it from current ADC payloads [4] Recent Developments - Akari Therapeutics recently participated in a Virtual Investor segment where CEO Abizer Gaslightwala discussed the issuance of India Patent No. 562,919 for "Thailanstatin Analogs," which covers claims for its PH1 payload and ADC technology [3] - The PH1 payload has shown significant activity in preclinical studies, inducing cancer cell death and activating immune cells, leading to robust and durable activity [4] Product Pipeline - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors [4] - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has potential synergistic effects with checkpoint inhibitors [4]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [3] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [3] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers a novel PH1 payload directly into tumors [3] - PH1 is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [3] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs [3] Synergistic Potential - AKTX-101 has shown potential for synergy with checkpoint inhibitors, demonstrating prolonged survival both as a single agent and in combination with these inhibitors [3] Upcoming Presentation - Abizer Gaslightwala, President and CEO of Akari, will present recent corporate events at the Virtual Biotech Investment Webinar on May 29, 2025 [1][2]

Core Insights - Akari Therapeutics is focused on developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat various cancer tumors [1][2] - The company appointed Mark Kubik as the new Head of Business Development for Oncology, enhancing its executive team with deep oncology experience [2] - Akari's lead asset, AKTX-101, targets the Trop2 receptor and utilizes the innovative PH1 payload, which is a spliceosome inhibitor designed to induce cancer cell death while activating immune responses [8] Financial Performance - For Q1 2025, Akari reported a net loss of approximately $3.7 million, a decrease from $5.6 million in Q1 2024 [4][16] - Research and development expenses were $0.8 million in Q1 2025, down from $2.3 million in the same period of 2024, primarily due to the suspension of the HSCT-TMA clinical program [4] - General and administrative expenses decreased to approximately $2.7 million in Q1 2025 from $3.7 million in Q1 2024, attributed to reduced legal and professional fees [5] Pipeline and Development Milestones - The company is advancing a pipeline of potentially first-in-class ADC candidates, with significant tumor-killing activity observed in preclinical models [2] - Upcoming milestones include presenting preclinical data on the PH1 payload's immuno-oncology activity at a scientific conference in the second half of 2025 [6] - Akari is exploring preclinical activity for AKTX-101 in various solid tumor indications and seeking strategic partners for research collaborations [6] Cash Position and Funding - As of March 31, 2025, Akari had cash of approximately $2.6 million, with net proceeds from a March 2025 offering totaling around $6.0 million [7] - The company continues efforts to out-license non-core assets in inflammation, ophthalmology, and rare diseases to generate non-dilutive capital for its ADC platform [3]